Corcept Therapeutics (CORT) Non-Current Assets (2010 - 2026)
Corcept Therapeutics (CORT) posted Non-Current Assets of $449.0 million for Q2 2026, up 15.48% sequentially from $388.8 million in Q1 2026, and up 25.21% YoY from $358.6 million in Q2 2025.
Corcept Therapeutics (CORT) Non-Current Assets (2010 - 2026) Analysis & Trends
Corcept Therapeutics has reported Non-Current Assets for 17 years, with the latest figure at $449.0 million in Q2 2026.
- Quarterly Non-Current Assets rose 25.21% year-over-year to $449.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 billion (up 1.29% YoY) and the FY2025 annual result came in at $351.2 million, down 4.81% from the prior year.
- Non-Current Assets climbed to $449.0 million in Q2 2026 per CORT's latest filing, from $388.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $449.0 million in Q2 2026 and troughed at $77.3 million in Q2 2022.
- A 5-year average of $225.2 million and a median of $162.7 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets tumbled 55.94% in 2022, then surged 167.39% in 2025.
- Over 5 years, Non-Current Assets stood at $84.2 million in 2022, then surged by 93.5% to $162.9 million in 2023, then soared by 126.52% to $369.0 million in 2024, then declined by 4.81% to $351.2 million in 2025, then gained by 27.86% to $449.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $449.0 million, $388.8 million, and $351.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Corcept Therapeutics | 12.37 Bn | 12.07 Bn | 252.09 Mn | 449.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 449.03 Mn |
| Mar 31, 2026 | 388.85 Mn |
| Dec 31, 2025 | 351.19 Mn |
| Sep 30, 2025 | 282.48 Mn |
| Jun 30, 2025 | 358.61 Mn |
| Mar 31, 2025 | 407.95 Mn |
| Dec 31, 2024 | 368.95 Mn |
| Sep 30, 2024 | 317.28 Mn |
| Jun 30, 2024 | 153.71 Mn |
| Mar 31, 2024 | 152.57 Mn |
| Dec 31, 2023 | 162.88 Mn |
| Sep 30, 2023 | 162.50 Mn |
| Jun 30, 2023 | 92.04 Mn |
| Mar 31, 2023 | 83.96 Mn |
| Dec 31, 2022 | 84.18 Mn |
| Sep 30, 2022 | 80.85 Mn |
| Jun 30, 2022 | 77.32 Mn |
| Mar 31, 2022 | 79.90 Mn |
| Dec 31, 2021 | 157.29 Mn |
| Sep 30, 2021 | 183.50 Mn |